Logo image of ALNEV.PA

NEOVACS (ALNEV.PA) Stock Price, Quote, News and Overview

EPA:ALNEV - Euronext Paris - Matif - FR001400TG47 - Common Stock - Currency: EUR

0.0024  0 (0%)

ALNEV.PA Quote, Performance and Key Statistics

NEOVACS

EPA:ALNEV (6/20/2025, 7:00:00 PM)

0.0024

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High442
52 Week Low0
Market Cap4.97K
Shares2.07M
Float2.07M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO04-15 2010-04-15


ALNEV.PA short term performance overview.The bars show the price performance of ALNEV.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

ALNEV.PA long term performance overview.The bars show the price performance of ALNEV.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALNEV.PA is 0.0024 EUR. In the past month the price decreased by -52%. In the past year, price decreased by -100%.

NEOVACS / ALNEV Daily stock chart

ALNEV.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.12 285.45B
AMG.DE AMGEN INC 13.98 135.53B
1GILD.MI GILEAD SCIENCES INC 14.1 117.83B
GIS.DE GILEAD SCIENCES INC 13.94 116.51B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 99.95B
1REGN.MI REGENERON PHARMACEUTICALS 11.93 49.56B
ARGX.BR ARGENX SE 101.31 28.77B
22UA.DE BIONTECH SE-ADR N/A 21.95B
IDP.DE BIOGEN INC 8.07 16.25B
0QF.DE MODERNA INC N/A 8.56B
1MRNA.MI MODERNA INC N/A 8.44B
1HALO.MI HALOZYME THERAPEUTICS INC 11.73 5.71B

About ALNEV.PA

Company Profile

ALNEV logo image Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The company is headquartered in Suresnes, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2010-04-15. The company specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The firm researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The firm focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The firm operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.

Company Info

NEOVACS

14 Rue De La Republique

Suresnes ILE-DE-FRANCE FR

Employees: 22

ALNEV Company Website

ALNEV Investor Relations

Phone: 33153109300

NEOVACS / ALNEV.PA FAQ

What is the stock price of NEOVACS today?

The current stock price of ALNEV.PA is 0.0024 EUR.


What is the ticker symbol for NEOVACS stock?

The exchange symbol of NEOVACS is ALNEV and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALNEV.PA stock listed?

ALNEV.PA stock is listed on the Euronext Paris - Matif exchange.


What is NEOVACS worth?

NEOVACS (ALNEV.PA) has a market capitalization of 4.97K EUR. This makes ALNEV.PA a Nano Cap stock.


How many employees does NEOVACS have?

NEOVACS (ALNEV.PA) currently has 22 employees.


Should I buy NEOVACS (ALNEV.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NEOVACS (ALNEV.PA) stock pay dividends?

ALNEV.PA does not pay a dividend.


What is the Price/Earnings (PE) ratio of NEOVACS (ALNEV.PA)?

NEOVACS (ALNEV.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-33334.67).


ALNEV.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALNEV.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ALNEV.PA. ALNEV.PA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALNEV.PA Financial Highlights

Over the last trailing twelve months ALNEV.PA reported a non-GAAP Earnings per Share(EPS) of -33334.67. The EPS increased by 64.66% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -149.13%
ROE -182.23%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%99.98%
Sales Q2Q%-90.49%
EPS 1Y (TTM)64.66%
Revenue 1Y (TTM)-45.39%

ALNEV.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to ALNEV.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts86.67
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A